{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Uddin MJ"],"funding":["National Cancer Institute","NCI NIH HHS","V Foundation for Cancer Research","NIH HHS"],"pagination":["9251-9261"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6545551"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(5)"],"pubmed_abstract":["In vivo targeting and visualization of cyclooxygenase-1 (COX-1) using multimodal positron emission tomography/computed tomography imaging represents a unique opportunity for early detection and/or therapeutic evaluation of ovarian cancer because overexpression of COX-1 has been characterized as a pathologic hallmark of the initiation and progression of this disease. The furanone core is a common building block of many synthetic and natural products that exhibit a wide range of biological activities. We hypothesize that furanone-based COX-1 inhibitors can be designed as imaging agents for the early detection, delineation of tumor margin, and evaluation of treatment response of ovarian cancer. We report the discovery of 3-(4-fluorophenyl)-5,5-dimethyl-4-(<i>p</i>-tolyl)furan-2(5<i>H</i>)-one"],"journal":["ACS omega"],"pubmed_title":["Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer."],"pmcid":["PMC6545551"],"funding_grant_id":["CA136465","P01 CA077839","CA182850-01A1","R01 CA089450","P50 CA128323","CA89450","CA128323-4, -5","R15 CA182850","U54 CA136465","S10 OD017997"],"pubmed_authors":["Marnett LJ","Malerba P","Kingsley PJ","Jashim E","Uddin MJ","Uddin MI","Daniel CK","Manning HC","Tantawy MN","Nickels ML","Wilson AJ","Ghebreselasie K","Khabele D","Crews BC"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.","description":"In vivo targeting and visualization of cyclooxygenase-1 (COX-1) using multimodal positron emission tomography/computed tomography imaging represents a unique opportunity for early detection and/or therapeutic evaluation of ovarian cancer because overexpression of COX-1 has been characterized as a pathologic hallmark of the initiation and progression of this disease. The furanone core is a common building block of many synthetic and natural products that exhibit a wide range of biological activities. We hypothesize that furanone-based COX-1 inhibitors can be designed as imaging agents for the early detection, delineation of tumor margin, and evaluation of treatment response of ovarian cancer. We report the discovery of 3-(4-fluorophenyl)-5,5-dimethyl-4-(<i>p</i>-tolyl)furan-2(5<i>H</i>)-one","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-18T14:12:36.379Z","creation":"2019-07-24T07:08:12Z"},"accession":"S-EPMC6545551","cross_references":{"pubmed":["31172046"],"doi":["10.1021/acsomega.9b01093"]}}